Video

Lack of Durable Responses in Current Treatment of mCRC

Insight on the ongoing unmet needs in achieving durable responses in BRAFV600E-mutant metastatic colorectal cancer (mCRC).

Related Videos
5 KOLs are featured in this panel.
5 KOLs are featured in this panel.
Sam Brondfield, MD, MA
Ciara Kelly, MBBCh, BAO
Mark Agulnik, MD
Chun Chao, PhD, MS
Jonathan C. Trent, MD, PhD
5 KOLs are featured in this panel.
5 KOLs are featured in this panel.
Efficacy and Safety of Fruquintinib in Patients With Metastatic Colorectal Cancer According to Prior Treatment Sequence in the Refractory Setting: Results From FRESCO and FRESCO-2
Related Content
Shubham Pant, MD, MBBS
July 24th 2024

Zanidatamab Demonstrates Activity in Pretreated HER2+ Biliary Tract Cancer

Heinz-Josef Lenz, MD, FACP, about the prognostic and predictive value of HER2 gene expression for patients with KRAS wild-type metastatic colorectal cancer (mCRC). Lenz is a professor in the Department of Medicine and the Department of Preventive Medicine in the Division of Oncology at the University of Southern California (USC) Keck School of Medicine in Los Angeles. He also serves as the associate director of Clinical Research, chair of the Gastrointestinal Oncology Program, and co-director of the Colorectal Center at the USC Norris Comprehensive Cancer Center
June 3rd 2024

Lenz Discusses the Prognostic and Predictive Value of HER2 Gene Expression in KRAS Wild-Type mCRC

Tanios S. Bekaii-Saab, MD, FACP, of the Mayo Clinic
July 19th 2024

Complexity in GI Cancer: Questions Are Answered in Gastroesophageal Cancer, Remain in HCC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Botensilimab/Baltstilimab in MSS CRC | Image Credit: © Dr_Microbe - stock.adobe.com
July 18th 2024

FDA Advises Against Accelerated Approval Pathway for Botensilimab/Balstilimab in R/R MSS CRC

Tanios S. Bekaii-Saab, MD
July 18th 2024

Longest OS Reported From a Third-Line mCRC Randomized Trial Is Seen in ARC-9 Study